Last reviewed · How we verify
Antiandrogen+docetaxel
This combination blocks androgen signaling while simultaneously disrupting microtubule dynamics to inhibit cancer cell proliferation and survival.
This combination blocks androgen signaling while simultaneously disrupting microtubule dynamics to inhibit cancer cell proliferation and survival. Used for Metastatic castration-resistant prostate cancer (mCRPC), Metastatic hormone-sensitive prostate cancer (mHSPC).
At a glance
| Generic name | Antiandrogen+docetaxel |
|---|---|
| Also known as | Taxotere |
| Sponsor | Göteborg University |
| Drug class | Combination therapy: androgen receptor antagonist + taxane chemotherapy |
| Target | Androgen receptor (AR) and microtubule-associated proteins |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The antiandrogen component antagonizes androgen receptor signaling, which is critical for prostate cancer cell growth and survival. Docetaxel, a taxane chemotherapy agent, stabilizes microtubules and prevents their disassembly, leading to cell cycle arrest and apoptosis. Together, these agents target complementary pathways in hormone-sensitive and castration-resistant prostate cancer.
Approved indications
- Metastatic castration-resistant prostate cancer (mCRPC)
- Metastatic hormone-sensitive prostate cancer (mHSPC)
Common side effects
- Neutropenia
- Fatigue
- Nausea/vomiting
- Diarrhea
- Peripheral neuropathy
- Anemia
- Alopecia
Key clinical trials
- A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer
- PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
- A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants (PHASE1)
- Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel (PHASE2)
- Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (PHASE2)
- Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer (PHASE2)
- Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer (PHASE2)
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiandrogen+docetaxel CI brief — competitive landscape report
- Antiandrogen+docetaxel updates RSS · CI watch RSS
- Göteborg University portfolio CI